A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy Meeting Abstract
| Authors: | Hussain, M.; Rathkopf, D. E.; Liu, G.; Armstrong, A. J.; Kelly, W. K.; Ferrari, A. C.; Hainsworth, J. D.; Yang, L.; Schwartz, J. D.; Higano, C. S. |
| Abstract Title: | A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy |
| Meeting Title: | 2012 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2012 Feb 2-4 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-02-10 |
| Language: | English |
| ACCESSION: | WOS:000208892400098 |
| DOI: | 10.1200/jco.2012.30.5_suppl.97 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 97 -- Source: Wos |
